Navigation Links
Endo Pharmaceuticals Raises 2011 Financial Guidance and Reports Strong Fourth Quarter 2010 Financial Results
Date:2/28/2011

Adjusted Diluted Earnings Per Share Guidance for 2011Year EndingDecember 31, 2011Projected GAAP diluted income per common share$2.43To$2.53Upfront and milestone-related payments to partners

$0.35$0.35Amortization of commercial intangible assets and inventory step-up

$1.33$1.33Acquisition and integration costs related to recent acquisitions.

$0.26$0.26Interest expense adjustment for ASC 470-20 and the amortization of the premium on debt acquired from Indevus

$0.16$0.16Tax effect of pre-tax adjustments at the applicable tax rates and certain other expected cash tax savings as a result of recent acquisitions

($0.33)($0.33)Diluted adjusted income per common share guidance $4.20To$4.30The company's guidance is being issued based on certain assumptions including:


  • Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results.
  • Includes all completed business development transactions as of February 28, 2011.
  • About Endo Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit www.endo.com.

    (Tables Attached)The following tables present Endo's unaudited Total Revenues for the three months ended December 31, 201
    '/>"/>

    SOURCE Endo Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. MAP Pharmaceuticals to Present Data on LEVADEX™ at the 63rd Annual Meeting of the American Academy of Neurology
    2. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
    3. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
    4. Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
    5. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
    6. UCLA and Sound Pharmaceuticals Identify a Key Hearing Regeneration Protein in the Human Inner Ear
    7. JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
    8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
    9. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
    10. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
    11. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... Sept. 18, 2014   Fruit Street Health ... initial seed round of funding. The ... by a series of individual investors, the majority of ... in the initial round are; Houston Cardiology Consultants ... Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
    (Date:9/18/2014)... 2014  KIYATEC announced today that it has ... Research (SBIR) Phase II Contract from the National ... and centers that comprise the National Institutes of ... year award, KIYATEC will expand its 3D breast ... forefront of cancer therapy strategies: 1) cancer,s interaction ...
    (Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... endothelial growth factor (VEGF) agent for wet AMD, is ... Advantage plans as Genentech,s Lucentis, which is the standard ... managed care organization (MCO) directors do not identify a ... slightly more likely than Lucentis to be listed on ...
    Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
    ... 31, 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd ... clinical study to confirm the efficacy of its novel ... trial is evaluating the efficacy, safety and tolerability of ... compared to vehicle. The trial consists of treating 132 ...
    ... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... BSTC ), a biopharmaceutical company, today announced ... Companies and announced plans to move XIAFLEX forward in ... as well as to collaborate on the initiation of ...
    Cached Medicine Technology:Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 2Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 2Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 4Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 5Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 6Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 7Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 8
    (Date:9/18/2014)... New York (PRWEB) September 18, 2014 ... lawsuits ( http://www.xareltolawsuitcenter.com ) currently pending in Pennsylvania’s ... have all claims filed on behalf of out-of-state ... motions filed on September 11th, the defendants maintain ... claims contained in the lawsuits have no connection ...
    (Date:9/18/2014)... 18, 2014 Memorial Cardiac and ... this week by performing the first ever, adult heart ... Network for Organ Sharing) approval to launch the adult ... only two programs in South Florida. , The ... Enrique Gongora, Medical Director of the Adult Heart ...
    (Date:9/18/2014)... people become more physically vulnerable during bereavement, new research ... during bereavement changes with age, British researchers say. As ... likely to have weakened immune systems and develop infections, ... months after loss, we can suffer from reduced neutrophil ... blood cell and as such are essential at combating ...
    (Date:9/18/2014)... September 18, 2014 One of the ... medical transport industry, ShandsCair Flight Program’s new ... Inc . (AHI) at the Air Medical Transport Conference ... delivered and placed into service ShandsCair EC155 and the ... be displayed at AMTC highlight Airbus Helicopters broad, industry ...
    (Date:9/18/2014)... 18, 2014 (HealthDay News) -- Daily supplements of selenium ... the development of age-related cataracts among men, a new ... one or both could help prevent cataracts. To investigate ... and Harvard Medical School in Boston, and his colleagues ... and vitamin E. The trial was initially designed to ...
    Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2
    ... ... to Sonitor’s Ultrasound RTLS Technology Platform strengthen further the technology’s position as the ... ... Sonitor Technologies, the world leader in ultrasound-based real time locating systems for hospitals ...
    ... ... ... , ... , , , ...
    ... patients who regularly received massages averaging 14 minutes or more ... over four weeks, according to results of a study reported ... Society. In the study, sponsored by the National Cancer ... program to provide massage to patients at home. The multi-ethnic ...
    ... The introduction of prostate-specific antigen (PSA) testing as a screening ... beginning of the 1990s drastically increased the detection of PCa. ... men with PCa. To assess the risk of suicide among ... study was carried out in Sweden. The results are published ...
    ... Copenhagen, led by postdoc Luke Holman of the Center for ... B , published on the 24 February 2010, that ant ... Often, an ant colony has more than one queen. Multiple ... increasing the chance the colony will survive the hazardous first ...
    ... ... wristbands market with line of ready-to-ship LaserBand® products that can be instantly priced and ... ... in providing a complete range of printed products and services, today announced the launch ...
    Cached Medicine News:Health News:Sonitor Technologies Announces New Staff Tag and Battery Powered Ultrasound Receiver 2Health News:Catholic Charities USA Calls for Affordable and Accessible Healthcare for All 2Health News:Catholic Charities USA Calls for Affordable and Accessible Healthcare for All 3Health News:Family members reduce stress in advanced cancer patients with 14 minute massages 2Health News:Plotting and treachery in ant royal families 2Health News:My1Stop.com Expands Into Medical Wristbands Market with Patented LaserBand Printable Wristbands 2Health News:My1Stop.com Expands Into Medical Wristbands Market with Patented LaserBand Printable Wristbands 3
    The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
    The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    Medicine Products: